ERBB2 and breast cancer: Using the HER2 positive breast cancer model SK-BR-3 cells, we identified a few compounds which robustly blocked NRG-induced HER3 phosphorylation and HER2–HER3 dimer downstream signalling, including Akt and ERK phosphorylation.